The U.S. National Institutes of Health rescinded a petition urging it to make use of a controversial provision of federal legislation to allow more people to access a cancer drug. This was done in a long-awaited decision.
The petition focused on the cost of the Xtandi drug for prostate cancer, which is listed at $160,000 to $180,000. The medicine was developed at the University of California, Los Angeles, with help from U.S. taxpayer dollars — specifically, grants from the NIH and the Department of Defense. UCLA Professor, who was later licensed the drug, was one the principal inventors.
Continue to STAT+ to read the full story…
